MediWound Ltd. (NASDAQ:MDWD) Short Interest Up 20.9% in January

MediWound Ltd. (NASDAQ:MDWD) was the target of a large growth in short interest in January. As of January 30th, there was short interest totaling 1,284,063 shares, a growth of 20.9% from the January 15th total of 1,062,079 shares. Approximately 11.0% of the company’s stock are short sold. Based on an average daily volume of 150,032 shares, the days-to-cover ratio is currently 8.6 days. Based on an average daily volume of 150,032 shares, the days-to-cover ratio is currently 8.6 days. Approximately 11.0% of the company’s stock are short sold.

Institutional Investors Weigh In On MediWound

Several hedge funds have recently bought and sold shares of the business. Quarry LP bought a new stake in shares of MediWound during the fourth quarter worth $26,000. BNP Paribas Financial Markets raised its position in shares of MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 723 shares in the last quarter. Russell Investments Group Ltd. grew its stake in MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 649 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 999 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in MediWound in the fourth quarter valued at approximately $109,000. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Price Performance

Shares of MDWD stock traded up $0.50 during trading on Tuesday, reaching $17.77. The company’s stock had a trading volume of 30,063 shares, compared to its average volume of 114,048. MediWound has a 1-year low of $14.14 and a 1-year high of $22.50. The stock’s 50-day moving average price is $18.08 and its 200 day moving average price is $17.95. The company has a market capitalization of $228.13 million, a price-to-earnings ratio of -9.35 and a beta of 0.13.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.57. The business had revenue of $5.43 million for the quarter, compared to analyst estimates of $6.56 million. MediWound had a negative net margin of 98.43% and a negative return on equity of 62.11%. On average, sell-side analysts anticipate that MediWound will post -2.66 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Thursday, January 22nd. Zacks Research raised MediWound from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. HC Wainwright reissued a “buy” rating and set a $36.00 price objective (up previously from $31.00) on shares of MediWound in a research note on Friday, November 21st. Finally, Wall Street Zen raised shares of MediWound from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, MediWound presently has an average rating of “Moderate Buy” and an average price target of $33.50.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.